Medgenics(Regs) Share Discussion Threads

[sicilian_kan] 30/1/2010 00:17

Another patent approval:

TIDMMEDG

RNS Number : 1885G
Medgenics Inc
27 January 2010

NEW PATENT APPROVAL BOOSTS INTELLECTUAL PROPERTY PORTFOLIO AT MEDGENICS

Misgav, Israel and London, UK - 27 January 2010 - Medgenics (AIM: MEDG and
MEDU), the biopharmaceutical company that creates therapeutic protein producing
implantable Biopumps announced today that the Japanese Patent Office has
approved patent application number 2003-550677 titled CLOSED AUTOMATED SYSTEMS
FOR TISSUE BASED THERAPY DOSING AND ADMINISTRATION OF SAME. This strengthens the suite of over 60 approved patents and patent applications owned and licensed by the company which cover all aspects of the company's technology for producing autologous Biopumps that are capable of producing a wide range of therapeutic proteins when implanted into humans.

Dr. Andrew Pearlman, CEO of Medgenics commented:
"The granting of additional patents is always very important to a technology
driven company such as Medgenics. We now have issued or applied for patents in
all major jurisdictions covering key aspects of our platform technology for
obtaining micro-organs from a patient's tissue, processing them to produce
therapeutic proteins and then reinserting them into the patient to provide
continuous delivery of therapeutic proteins over an extended period of time".

[sicilian_kan] 27/1/2010 08:49

The following is worth reading from the admission document:

"Advantages of the Biopump Platform Technology The Board believes that the Biopump Platform Technology provides a wide range of advantages over existing therapies that appeal and offer benefits to doctors, patients and third-party payers (e.g. medical insurers). The advantages include:

Increased efficacy – the Directors believe that the sustained production and delivery (for four-six months or more) of protein within the therapeutic window obtained through a single procedure to implant sustained-action Biopumps is likely to be a more efficacious form of the desired protein treatment than offered by an extended series of repeat bolus injections. Maintaining effective levels of protein within the therapeutic window in the patient optimises efficiency and eliminates overshoot and undershoot (and their respective significant therapeutic and side effect downsides).

Improved safety – in view of recent regulatory concerns over safety and increased mortality risks associated with EPO delivery using conventional bolus injections, the Directors believe that the delivery of EPO (for a period of four-to-six months or more), obtained through a single procedure to implant Biopumps that may be regulated through ablation techniques, will make it easier to avoid the dangers of overdose. Further, the Board believe that the protein produced by Biopumps should be safer, since it is produced from the patient's own tissue instead of from animal cells. Recombinant proteins from non-human mammalian cells may have different glycosylation patterns from those of human cells, causing the formation of antibodies in some patients that can result in immune rejection of the protein, even against the patient's own native proteins, such as in PRCA in EPO therapy. By contrast, producing protein from the patient's own cells is expected to reduce the risk of immune responses, since these proteins are produced as closely as possible to the natural proteins, which the patient lacks.

Reversible treatment – unlike gene therapy, the Biopump procedure is reversible. Tests have demonstrated that Biopumps can be ablated by laser, radiofrequency needle, or (if necessary) a surgical procedure to reduce or halt protein production and secretion by a Biopump. The Group is seeking to refine its techniques for successfully locating Biopumps after insertion to enable it to ablate the protein production properties and secretion of the Biopumps when required.

Reduced side effects – the Directors believe that the Group's therapy will have fewer and less severe side effects associated with it than are associated with current recombinant protein production and delivery methods. Instead of bolus injections, the Directors believe that the Biopump Platform Technology will provide efficient, sustained EPO delivery within the desired therapeutic range and should eliminate the health risks and side effects associated with the overshoot typical of each bolus injection. Overshoots with proteins such as IFN-αare typically associated with severe flu-like symptoms and other serious side effects, which the Directors believe will be much reduced or even prevented with the INFRADURE approach. Undershoots between bolus injections not only undertreat the patient's illness, but with EPO therapy, could also lead to conditions such as neocytolysis.

Lower costs – the Directors expect that the Biopump Platform Technology will offer a costeffective protein therapy. The Biopump Platform Technology does not require a protein production facility to produce protein, thereby eliminating the need for an outlay of hundreds of millions of US dollars to build such a facility, which would be needed to meet the anticipated growing protein demand. The Directors expect that, once fully developed, the devices used in the Biopump platform will be sufficiently automated such that, together with the use of sealed 25 cartridges and other single-use items, they will enable the practical and reliable implementation of Biopump therapy and the Group will be able to lower the per-patient cost of Protein therapy significantly. The Directors also believe that automation of the process will allow Biopump therapy to be performed in conventional hospitals and clinics worldwide rather than being sent off for expensive and time-consuming laboratory processing.

Eliminating frequent injections – the sustained-action Biopump typically requires only two clinic visits: one for the harvesting of the MOs and the second for the implantation of the sustainedaction Biopumps. Conventional therapy requires extended periods of frequent injections, which decrease both patient compliance and quality of life, while increasing cost.

Extended treatment to undertreated populations – the Directors believe that the Biopump Platform Technology will enable extension of treatment to under-treated populations. Patients who cannot continue hepatitis C treatment because of the severe side effects of conventional injections are, the Directors believe, more likely to be able to do so with the sustained-action Biopump."

[sicilian_kan] 25/1/2010 08:20

Header updated.

I note the current market cap is now just £8m.

[sicilian_kan] 23/1/2010 13:38

Crimeprotection1. Welcome to the thread. I also think this share is too good to be true, for the reasons in the header.

In relation to fundraisers, under the Hemophilia agreement signed with the market leader in that field, they got $4m for a one year contract, with up to £3m more dependent on results.

This should keep MEDG going for some time, even if no other deals are signed. So I am not expecting any major dilution. But yes, if it happened, the shares are still cheap.

As for the death of Lord Steinberg, it was a great shame as he was a huge supporter of the company and backed it up with his money. Fortunately, Joel Kanter is an even bigger backer and Lord Steinberg's role was not the tech side, which helps. May be a reason why we have been without news for a while as he would have been involved in the deal negotiations; cannot see this position lasting too much longer.

[crimeprotection1] 14/1/2010 21:22

Hi all,

Been having a look at this one over last few days, seems to be too good to be true and it normally is although with the odd exception, this seems on the face of it to be one of those exceptions and I intend to buy a modist amount and place in the bottom drawer! My only concern is the need for further fundraisers, although with such a small market cap I suppose they could in theory double the current amount of shares in issue and this could still look cheap in medium to long term. So sad regarding the director, just noticed that he was only buying shares a few days before!

[sicilian_kan] 14/1/2010 17:45

Maybe it was the only share they had...

[dawsonpaul] 14/1/2010 17:06

Er - what's with the massive trade today?

[sicilian_kan] 15/12/2009 11:18

Hi dp. They appear to be doing everything right here now. Would be very surprised not to see a good return in the coming months.

[sicilian_kan] 09/12/2009 08:24

My market cap calculation is as follows:

MEDG 97,266,575 shares * 0.0775; +
MEDU 21,154,119 shares * 0.0725; =

£9,071,833.19 market cap.

[sicilian_kan] 09/12/2009 08:14

I cannot believe that this share did not rise on the recent news. We now have confirmation that they have:

1. Partnered their the third treatment in their pipeline, which is pre-clinical and significantly behind the other two such as the proven Phase I EPODURE, for $7m to take it to Phase I, with an option agreement thereafter, with a market leader in hemophilia.

2. Got in one of the top world experts for their second treatment in their pipeline, which is also pre-clinical but due to move into trials next year.

3. Had up to 12 months without injections for their Phase I lead therapy EPODURE, when 1-3x weekly injections were previously required.

4. They are in active discussions to partner 2. and 3. as well as other potential areas.

The newsflow potential in the short term is huge, and MEDG now have a market cap of just £9m for a multi-blockbuster therapy treatment, validated by the recent deal and recruitment of the world expert.

[sicilian_kan] 07/12/2009 08:21

First class news out today. This is basically the number 1 guy in the world that they have recruited. Astonishing that an AIM microcap can recruit him and a real thumbs up validation for medgenics tech. Will be really good to have him on board for the trials too as he will carry great weight with the regulatory bodies.

---

RNS Number : 6537D
Medgenics Inc
07 December 2009

WORLD EXPERT ON LIVER DISEASE JOINS THE SCIENTIFIC
ADVISORY BOARD OF MEDGENICS

DR BRUCE BACON TO SUPPORT DEVELOPMENT OF COMPANY'S INNOVATIVE
HEPATITIS-C TREATMENT

Misgav, Israel and London, UK - 07 December 2009 - Medgenics (AIM: MEDG and MEDU), the biopharmaceutical company that creates implantable therapeutic protein producing Biopumps announced today that Dr. Bruce R. Bacon was appointed to the Scientific Advisory Board of the Company.

Dr. Bacon is a former President of the American Association for the Study of Liver Diseases (AASLD) and a recognised World expert on Hepatitis. Dr. Bacon is the James F. King, MD Endowed Chair in Gastroenterology, Professor of Internal Medicine, and Director of the Division of Gastroenterology and Hepatology at Saint Louis University School of Medicine in St. Louis, Missouri. The potential treatment of Hepatitis using the Company's patented INFRADURE technology is one of the core projects that the Company is seeking to commercialise. Medgenics reported consistently promising and unprecedented results from the safety and efficacy clinical trial of its EPODURE Biopumps for sustained anaemia treatment from a single administration, in progress since September 2008. Biopumps are made from tissue taken by needle biopsy taken from under the patient's own skin and processed to become implantable biofactories to provide the required therapeutic protein for many months. The INFRADURE technology has been similarly used to create implantable Biopumps that produce Interferon Alpha for months and will offer a significant addition to the physician's Hepatitis armamentarium to treat this scourge of a disease.

Dr. Eugene Bauer, Chairman of Medgenics commented:

"We are delighted to welcome Dr. Bacon to Medgenics. As one of the world's top experts in Hepatitis C, he brings a wealth of experience and influence to the company. Hepatitis is one of the core areas of treatment that we are seeking to commercialise. Having an expert of Dr. Bacon's calibre is essential as we move into the clinic with the exciting new approach to treatment that our INFRADURE technology offers. Our ability to attract leading figures such as Dr. Bacon demonstrates the growing stature of Medgenics in the global market for therapeutic protein delivery. I and the rest of the Board look forward to working with him as we continue to develop Medgenics."

Dr. Andrew Pearlman, CEO of Medgenics commented:

"The appointment of Dr. Bacon is another important addition to the senior team at Medgenics. Coming in the wake of the signing of a hemophilia development agreement with a major international biopharmaceutical company, Dr. Bacon's appointment is a further strong vote of confidence for Medgenics and our INFRADURE approach to interferon alpha therapy in the treatment of Hepatitis C."

[sicilian_kan] 05/11/2009 13:28

A sad announcement.

Medgenics, Inc.
('Medgenics' or the 'Company')

4 November 2009

It is with great sadness that the Company announces the death of Lord Leonard
Steinberg, Non-Executive Director, who died suddenly on the night of 2 November
2009.
Lord Steinberg served as a director of the Company since 1 February 2008 and the Board would like to record its sincere gratitude for the valuable contribution and support he gave to the Company during this period.
Andrew Pearlman, CEO, commented "The whole of the Board are greatly shocked and saddened to learn of the untimely death of Lord Steinberg, who was an invaluable member of our Board. Lord Steinberg made an invaluable contribution to the continuing development of Medgenics and supported the Company enormously over the last two years. He will be greatly missed by everyone at the Company. Our sincere condolences go to his wife and family at this sad time".

[phunky prophet] 05/11/2009 12:35

NOTE, ALL ENGLISHROSE2'S POSTS HAVE BEEN REMOVED! :-)